Search results
Is This a Setback for Moderna?
The Motley Fool via AOL· 2 days agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
Jim Cramer: This Industrial Company Is ‘Absolutely Terrific’, Recommends Buying Modine Manufacturing...
Benzinga· 15 hours agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna
Cramer's Lightning Round: 'I'm a believer' in Moderna
CNBC· 1 day ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to...
Smart Money Is Betting Big In MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 10 hours agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna MRNA ...
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
Motley Fool via Yahoo Finance· 4 days agoModerna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every...
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Zacks via Yahoo Finance· 3 days agoModerna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 7 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Motley Fool via Yahoo Finance· 7 days agoFive years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing...
FDA delays decision on Moderna RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.